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Abstract
Background: Recruitment of cofactors in the interaction of the androgen receptor (AR) and AR ligands plays a
critical role in determining androgenic/antiandrogenic effects of the AR ligand on signaling, but the functions of
key cofactors, including nuclear receptor coactivator (NCOA), remain poorly understood in prostate cancer cells
treated with AR ligands.
Methods: We examined prostate cancer cell lines LNCaP and VCaP expressing mutated and wild-type ARs,
respectively, to clarify the significance of NCOAs in the effect of antiandrogens. Hydroxyflutamide showed
antagonistic activity against VCaP and an agonistic effect on LNCaP. Bicalutamide served as an antagonist for both.
We analyzed mRNA transcription and protein expression of NCOAs in these cells pretreated with
dihydrotestosterone and thereafter treated with the mentioned antiandrogens. Transcriptional silencing of
candidate NCOAs and AR was performed using small interfering RNA (siRNA). Cell proliferation was evaluated with
MTT assay.
Results: LNCaP treated with bicalutamide showed an about four-fold increase in the expression of NCOA2 mRNA
compared to those pretreated with dihydrotestosterone alone (P <0.01). In VCaP pretreated with
dihydrotestosterone, transcriptions of NCOA2 and NCOA7 were slightly increased with bicalutamide (1.96- and 2.
42-fold, respectively) and hydroxyflutamide (1.33-fold in both). With Western blotting, the expression of NCOA2
protein also increased in LNCaP cells treated with bicalutamide compared with that in control cells pretreated with
dihydrotestosterone alone. Following silencing with siRNA for NCOA2, PSA levels in media with LNCaP receiving
bicalutamide were elevated compared with those in non-silencing controls (101.6 ± 4.2 vs. 87.8 ± 1.4 ng/mL,
respectively, P =0.0495). In LNCaP cells treated with dihydrotestosterone and bicalutamide, NCOA2-silencing was
associated with a higher proliferation activity compared with non-silencing control and AR-silencing.
Conclusion: NCOA2, which has been thought to be recruited as a coactivator, possibly plays a corepressive role in
AR of prostate cancer cells when treated with antiandrogens, suggesting its potential as a therapeutic target.
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Background
NR3C4 (nuclear receptor subfamily 3, group C, member 4),
also well-known as the androgen receptor (AR), is a mem-
ber of the nuclear hormone receptor superfamily of ligand-
regulated transcription factors [1, 2]. It has been well-
established that the androgen-AR interaction is involved in
the proliferation of both benign and malignant prostate epi-
thelial cells, and the role played by the androgen-AR inter-
action has been a therapeutic target [3, 4]. Androgen
deprivation therapy (ADT) has thus been the mainstay for
patients with metastatic prostate cancer and non-metastatic
high-risk disease to prevent recurrence after definitive local
therapy [5, 6].
Patients who have undergone ADT often show resist-
ance to it, and develop castration-resistant prostate can-
cer (CRPC) [2, 7]. Despite being refractory to ADT,
experimental studies as well as clinical practice suggest
that CRPC has AR, which remains transcriptionally and
functionally active beyond late-stage disease; human kal-
likrein (KLK) 3/prostate-specific antigen (PSA), whose
production is regulated by androgen-dependent tran-
scription, continues to elevate in the serum in men with
CRPC receiving ADT [2–4, 8]. Such contradictions can-
not be explained just by AR mutations or amplification
[9]. Recently, the agonistic or antagonistic role of the AR
ligand has been shown to be determined by the recruit-
ment profile of cofactors in the AR complex, and it has
also been suggested that the altered recruitment of co-
factors in the androgen-AR interaction and the signaling
pathway thereof are involved in the development of
CRPC, and possibly have an impact on oncological out-
comes [10–12]; however, relevant studies are limited.
Combined castration and peroral antiandrogens/AR-an-
tagonists have been associated with better survival out-
comes in men with prostate cancer compared with
castration alone, although some studies suggest that their
advantage may be limited in advanced disease [4, 5, 7].
Interestingly, antiandrogens represented by bicalutamide
and hydroxyflutamide can give an agonistic effect; cas-
trated men treated with antiandrogens, who have disease
progression thereafter, occasionally show an decrease in
serum PSA and improvement in disease following the dis-
continuation of them. This phenomenon of disease remis-
sion after the withdrawal of antiandrogens has been
regarded as antiandrogen-withdrawal syndrome, and men
showing such PSA reduction are associated with better
oncological outcomes [13–15]. Correspondingly, a few ex-
ploratory studies reported that commonly used antiandro-
gens showed agonistic activity in cells with increased AR
levels [16]; the altered arrangement or recruitment of
coactivators and corepressors to the promoters of AR tar-
get genes may account for the mentioned antagonist-
agonist conversion. Additionally, enhanced expressions of
AR possibly intensify signaling from low levels of residual
ligands, and change the normal response to antiandro-
gens, leading to resistance to them. However, roles played
by cofactors in AR complex in prostate cancer cells re-
main unclear; approaching them may clarify the mechan-
ism of castration resistance as well as antiandrogen
withdrawal syndrome, potentially developing innovative
therapy.
In the present study, we examined the expression pro-
file of AR cofactors in prostate cancer cells under vari-
ous hormonal conditions in the presence/absence of
antiandrogens to clarify the significance of nuclear re-
ceptor coactivators (NCOAs) in the effect of antiandro-
gens, and to identify cofactors as targets for prostate
cancer treatment.
Methods
Cells, agents, and antibodies
The protocol of this research project was approved by a
suitably constituted Ethics Committee of Niigata Univer-
sity School of Medicine (#2050), and all experimental
protocols for cell experimentation did not require ethical
review and approval. Human prostate cancer cell lines
LNCaP and VCaP were purchased from the American
Type Culture Collection (Manassas, VA, USA). Hydroxy-
flutamide and bicalutamide, antagonists against AR,
were purchased from Toronto Research Chemicals Inc.
(Toronto, Canada) and Tocris Bioscience (Bristol, UK),
respectively. Testosterone and dihydrotestosterone
(DHT) were purchased from Steraloids (Wilton, NH,
USA). Anti-NCOA2 (ab10491, Lot: GR167494-1) was
obtained from Abcam plc. (CAMRIDGE, UK). Anti-beta
actin (A5441, Lot: 122M478V) was obtained from
SIGMA-ALDRICH Corp. (St. Louis, MO, USA).
Cell culture
Cells were cultured in Roswell Park Memorial Institute-
1640 (Gibco; Life Technologies, Carlsbad, CA, USA),
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS), 1 % MEM nonessential amino acids, 1 %
sodium pyruvate solution 100 mM, 0.14 % NaHCO3, and
80 mg/L of kanamycin, at 37 °C in a humidified, 5 %
CO2 atmosphere. These cells grown to subconfluence
were switched to steroid hormone-depleted medium
without phenol-red, containing 10 % charcoal-dextran
stripped FBS (Biowest, Paris, France), and were then ex-
posed to hydroxyflutamide or bicalutamide at 10−5 M
for 3 days. For the Tandem-R PSA test (Beckman
Coulter Inc., San Diego, CA, USA) in media, cells were
plated at a population of 1 × 105 cells/mL in triplicate.
RNA extraction and quantification of gene expression by
quantitative-PCR
We analyzed mRNA transcription levels of cofactors in
LNCaP and VCaP cells pretreated with DHT of 10−9 M
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and thereafter treated with bicalutamide or hydroxyfluta-
mide at 10−5 M. mRNA expressions of AR-related genes
were determined by quantitative PCR. Cells were plated
at a concentration of 5 × 105 cells per 25-cm2 flasks
(5 mL of media) (Falcon Labware, Lincoln Park, NJ,
USA) for RNA isolation. Total RNA was isolated with
Ambion’s RNAqueous-4PCR Kit (Applied Biosystems;
Life Technologies) and cDNA was synthesized by
reverse-transcription according to the protocol of the
High-Capacity cDNA Reverse Transcription Kits (Ap-
plied Biosystems). The expression levels of genes and
the internal reference beta-actin were estimated using
quantitative PCR with the TaqMan system and ABI 7500
Sequence Detection System (Applied Biosystems). The de-
tectors/probes were purchased from Applied Biosystems.
Each experiment was triplicated, and we used the delta-
delta Ct method for analysis. An increase with ratio values
of 2.5-fold or higher in the transcription was considered
indicative of significant overexpression [17, 18].
Transcriptional silencing using small interfering RNA
(siRNA)
LNCaP cells (passage number: 19 times) cultured in ster-
oid hormone-depleted media containing 10 % charcoal-
dextran stripped FBS were treated with 10−9 M DHT,
and were prepared for the transfection of si-RNAs. A
total of 5 × 105 LNCaP cells were resuspended in 100 μL
of buffer R with 5 × 10−6 M siRNA for NCOA2 or con-
trol non-silencing siRNA, and were transfected in
100 μL of Neon tip with the Neon transfection system
(Life Technologies) using two pulses (1,100-V input
pulse voltage/20-ms input pulse width). NCOA2-trans-
fected cells were plated at a concentration of 1 × 105 cells/
mL per 25-cm2 flasks, and cultured in phenol-red free
media with 10 % charcoal-dextran stripped of FBS with
DHT of 10−9 for 3 days before the experiment. Functions
of cofactors with small interfering RNA (siRNA)-based si-
lencing were evaluated by measuring the concentration of
PSA in cell culture media [19].
Protein extract and Western blot assays
The cell tissues were prepared in lysis solution (PBS con-
taining 1.0 % Triton-X 100 and 20 mM HEPES), and the
supernatant was collected after being centrifuged at
25,000 × g for 30 min at 4 °C. Aliquots of proteins (24 μg
of each sample) were prepared using sample buffer, heated
for denaturing at 70 °C for 10 min, and separated on a
10 % Bis-Tris SDS-PAGE gel. Subsequently, they under-
went electrophoresis and were transferred to PVDF mem-
branes using iBlot Gel Transfer Stacks and the iBlot Dry
Blotting System (Novex; Life Technologies). Membranes
were preincubated for one hr at room temperature with
blocking buffer (5 % skim milk and 0.1 % Tween20 in
PBS), and incubated with the first antibody (NCOA2
[ab10491], 1:500 dilution) overnight at 4 °C. Thereafter,
membranes were exposed to peroxidase-labeled second
antibodies for 1 h at room temperature. Protein expres-
sions were visualized using the ECL Prime System (GE
Healthcare, Buckinghamshire, UK) and a cooled CCD
camera system (AE-9300z, ATTO CORP, Tokyo, Japan).
MTT assay
A total of 5 × 105 LNCaP cells were resuspended in
10 μL of buffer R with 5 × 10−6 M siRNA for NCOA2,
AR, or non-silencing control, and were transfected in
10 μL of Neon tip with the Neon transfection system
(Life Technologies) using two pulses (1,100-V input
pulse voltage/20-ms input pulse width). Cells were
plated at a concentration of 5 × 105 cells/mL per 96-well
assay plate, and were cultured in phenol-red free media
with 10 % charcoal-dextran stripped of FBS with DHT
of 10−9. Twenty μl of Celltiter 96 AQueous One Solution
Reagent (Promega, Fitchburg, WI, USA) were pipetted
into wells containing 100 μl of culture medium, incu-
bated the plate at 37 °C in a humidified, 5 % CO2 atmos-
phere, and subsequently, the absorbance at 490 nm was
recorded using iMARK (BIO-RAD, Hercules, CA, USA).
Assays were performed every 24 h for 3 days.
Statistical analysis
The Kruskal-Wallis test was used to verify the signifi-
cance in differences in expression level of mRNA and
cell proliferation analysis with MTT assay. The Mann–
Whitney U test was used to compare changes in paired
parameters before and after siRNA. The test was two-
sided and p < 0.05 was considered significant. All ana-
lyses were performed using SPSS version 15.0 J (SPSS
Inc., Chicago, IL, USA) on a Windows-based computer.
Results
Effects of bicalutamide or hydroxyflutamide treatment on
KLK3/PSA and AR transcription in prostate cancer cells
pretreated with DHT
In VCaP cells cultured in DHT-added media, the tran-
scription level of KLK3/PSA with quantitative PCR was
markedly reduced with bicalutamide treatment (0.05-
fold, Fig. 1); this was also the case with hydroxyflutamide
treatment (0.04-fold, Fig. 2). In LNCaP cells pretreated
with DHT, KLK3/PSA transcription was downregulated
with bicalutamide treatment (0.28-fold, Fig. 3), while
hydroxyflutamide treatment clearly increased the tran-
scription level of KLK3/PSA (2.90-fold, Fig. 4).
In VCaP cells cultured in DHT-added media, bicaluta-
mide and hydroxyflutamide treatment significantly up-
regulated the transcription of AR (3.39- and 2.51-fold,
respectively) (Figs. 1 and 2). In LNCaP cells pretreated
with DHT, bicalutamide treatment slightly increased
AR transcription (1.24-fold, Fig. 3), whereas AR
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transcription decreased with hydroxyflutamide (0.44-
fold, Fig. 4).
Impact of bicalutamide or hydroxyflutamide treatment on
the transcription of NCOA and nuclear receptor
corepressor (NCOR) families
Transcriptions of NCOA2 and NCOA7 were also ele-
vated with bicalutamide (1.96- and 2.42-fold, respect-
ively, Fig. 1) and hydroxyflutamide (1.33-fold in both,
Fig. 2) in VCaP cells pretreated with DHT. LNCaP cells
pretreated with DHT receiving bicalutamide showed a
4-fold increase in the expression of NCOA2 mRNA
compared with those cultured with DHT pretreatment
alone (Fig. 3); transcription levels of other coactivators
such as NCOA1, NCOA3, and NCOA4 did not increase
with bicalutamide. Also, corepressors such as NCOR1
and NCOR2 did not show an increase in the transcrip-
tion level.
Influence of knock-down of NCOA2 in LNCaP cells on the
production of KLK3/PSA
We also established knock-down models of NCOA2
in LNCaP cells with transcriptional silencing using
small interfering RNA (siRNA). Transcription levels
of NCOA2 were significantly reduced compared with
negative controls (Fig. 5). Thereafter, knock-down of
NCOA2 with siRNA showing most efficient silencing
was performed in LNCaP cells pretreated with DHT;
the KLK3/PSA concentration in media increased
compared with that in non-silencing controls (Fig. 6,
P =0.0495).
Fig. 1 Alterations in transcription of androgen receptor (AR), NCOAs,
NCORs, and human kallikrein 3/prostate-specific antigen (KLK3) in
VCaP cells pretreated with dihydrotestosterone (DHT) and thereafter
cultured with the addition of bicalutamide (BC). Relative mRNA
expression levels were assessed in comparison with those in cells
treated with DHT alone
Fig. 2 Transcriptional alterations of androgen receptor (AR), NCOAs,
NCORs, and human kallikrein 3/prostate-specific antigen (KLK3) in
VCaP cells pretreated with dihydrotestosterone (DHT) and
subsequently cultured with the addition of hydroxyflutamide (HF).
Relative mRNA expression levels were evaluated by comparing those
in cells treated with DHT alone
Fig. 3 Alterations in transcription of androgen receptor (AR), NCOAs,
NCORs, and human kallikrein 3/prostate-specific antigen (KLK3) in
LNCaP cells pretreated with dihydrotestosterone (DHT) and
thereafter cultured with the addition of bicalutamide (BC). Relative
mRNA expression levels were assessed in comparison with those in
cells treated with DHT alone. *P < 0.01 (Kruskal-Wallis test)
Fig. 4 Transcriptional alterations of androgen receptor (AR), NCOAs,
NCORs, and human kallikrein 3/prostate-specific antigen (KLK3) in
LNCaP cells pretreated with dihydrotestosterone (DHT) and
subsequently cultured with the addition of hydroxyflutamide (HF).
Relative mRNA expression levels were evaluated in comparison with
those in cells treated with DHT alone
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Protein expressions of NCOA2 in LNCaP cells cultured
with DHT and bicalutamide
With Western blotting, LNCaP cells pretreated with
DHT showed an increased protein level of NCOA2 with
bicalutamide than those without (Fig. 7).
Alterations in cell proliferation of LNCaP with silencing of
NCOA2 or AR
There was no difference among proliferations in the
NCOA2-silencing, AR-silencing, and non-silencing cells
cultured with dihydrotestosterone alone (Fig. 8). Relative
absorbance with MTT assay in LNCaP cells cultured
with DHT plus bicalutamide was shown in Fig. 9. Cells
with NCOA2-silencing showed a higher proliferation ac-
tivity compared with non-silencing control cells and
those with AR-silencing.
Discussion
LNCaP and VCaP cells have mutated and wild-type AR,
respectively [20, 21]. Hydroxyflutamide has an agonistic
effect on LNCaP cells, and bicalutamide serves as an an-
tagonist against them [22, 23]. For VCaP cells, the effect
of these antiandrogens has not been determined. In the
current study, both bicalutamide and hydroxyflutamide
treatments reduced KLK3/PSA transcription in VCaP
cells (Figs. 1 and 2), while the former decreased and the
latter increased KLK3/PSA transcription in LNCaP
(Figs. 3 and 4), suggesting the different nature of AR in
the response to antiandrogens between the two cell
types. The transcriptional regulation in AR in response
to antiandrogens also differed between VCaP and
LNCaP cells (Figs. 1, 2, 3 and 4), but bicalutamide inhib-
ited KLK3/PSA transcription in both VCaP and LNCaP
cells to a similar extent.
Fig. 5 The efficacy of siRNA for silencing NCOA2 in transcriptions.
1.00 ± 0.04 (control) vs. 0.29 ± 0.01, P = 0.0495
Fig. 6 Impact of knock-down of NCOA2 using siRNA on the produc-
tion of prostate-specific antigen (PSA) in LNCaP cells cultured with
dihydrotestosterone (DHT) plus bicalutamide (BC) (left columns) and
those treated with DHT alone. *101.6 ± 4.2 vs. 87.8 ± 1.4 ng/mL,
respectively, P = 0.0495, **144 ± 4.4 vs. 145 ± 5.6 ng/mL,
respectively, n.s
Fig. 7 Protein expression levels of NCOA2 with Western Blot in
LNCaP cells cultured with dihydrotestosterone (DHT) plus
bicalutamide (BC). The protein level of NCOA2 increased with
compared to that without BC
Fig. 8 Relative absorbance with MTT assay in LNCaP cells cultured
with dihydrotestosterone. There was no difference among
proliferations in the NCOA2-silencing, AR-silencing, and
non-silencing cells
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The present study verified that the absence of DHT
negated the role of antiandrogens; transcriptions of AR,
NCOAs, and KLK3/PSA were not altered by antiandro-
gens in the androgen-deprived milieu, except for KLK3/
PSA being increased by hydroxyflutamide. In the ab-
sence of endogenous ligands, AR is segregated in the
cytoplasm, with its nuclear localization sequence (NLS)
masked by heat-shock proteins. Binding to ligands and
the separation of these chaperones cause AR to
dimerize, and lead to conformational changes and the
exposure of the NLS [24–27]. Thus, the nuclear trans-
location of AR and binding to androgen response ele-
ments (AREs) activate androgen-responsive genes. This
process is transcriptionally regulated and post-
transcriptionally modified through various mechanisms
involving interactions with multiple coactivator and co-
repressor proteins [28–30]. AR activity is modulated by
the recruitment of multitudes of positive and negative
cofactors, being closely associated with the regulation of
protein stability, interaction with others, intracellular re-
ceptor localization, and alteration of the AR structure.
Thus, the elucidation of cofactor-related modifications
of AR may be a promising approach to develop novel
and efficient therapeutic options.
In our study, the transcription level of NCOA2 in-
creased with bicalutamide treatment in LNCaP cells
(Figs. 3 and 7); transcription levels of other coactivators
were not altered. On the other hand, such upregulation
of NCOA2 was not marked in VCaP, and the difference
may possibly be due to the aforementioned issues in AR
and the response to antiandrogens being different be-
tween the 2 types of cell. Moreover, knock-down of
NCOA2 in LNCaP cells increased the KLK3/PSA con-
centration in media (Figs. 5 and 6), and cell proliferation
analysis with MTT assay further supported the mentioned
novel finding (Figs. 8 and 9); NCOA2 is possibly associ-
ated with the downregulation of AR signaling in prostate
cancer cells treated with bicalutamide. In the presence of
bicalutamide, interestingly, knock-down of NCOA2 was
associated with a higher cell proliferation than knock-
down of AR. These results suggest that NCOA2 plays an
inhibitory role in prostate cancer cells treated with bicalu-
tamide. Steroid receptor coactivators represented by
NCOA2 and NCOA3 are key regulators, having multiple
effects, of transcription factors necessary for cancer cell
proliferation, survival, and metastasis [31]. Their overex-
pression and/or overactivation has been shown in a number
of human cancers with various genomic, transcriptional,
and posttranslational mechanisms, and are associated with
refractory disease leading to poor outcomes [31]. In human
prostate cancer, NCOAs have been reported to regulate cell
proliferation and invasion and be involved in castration re-
sistance, coupled with AR transcriptional activity [32–34].
NCOA2 has therefore been shown to play a role as a coac-
tivator in the androgen-AR interaction [35–38]; however,
there has been no study examining the function of NCOAs
in prostate cancer cells treated with antiandrogens. The
current results suggest that NCOA2 may possibly explain
the reduction of PSA on the withdrawal or conversion of
antiandrogens; it possibly also serves as a corepressor in the
presence of antiandrogens in prostate cancer cells pre-
treated with androgens. It is thus necessary to characterize
the functional and recruitment profile of each cofactor-AR
complex and signaling in prostate cancer in accordance
with antagonists as well as agonists.
The present study had several limitations. With the
current cell lines and hormonal milieu, cell proliferation
assays lack in reproducibility. Knock-down studies with
siRNA require further verification of the response, and
the application of different siRNAs is necessary to rule
out unrelated effects.
Conclusions
Although the recruitment of NCOA2 has been thought
to induce agonistic signaling in AR, the current study
showed that it possibly also serves as a corepressor in
the presence of antiandrogens in prostate cancer cells
cultured in a physiological hormonal milieu, suggesting
its potential as a therapeutic target for prostate cancer.
Characterization of the function and recruitment profile
of each cofactor related to AR signaling brought about
by various AR ligands may lead to advanced therapy for
men with prostate cancer.
Additional files
Additional file 1: Figure S1. Screening of the siRNA efficacy on target
mRNA expression levels. Catalog numbers were s20580, s20581, and
s20582 (Neon Transfection System; Life Technologies, Carlsbad, CA, USA)
Fig. 9 Relative absorbance with MTT assay in LNCaP cells cultured
with dihydrotestosterone (DHT) plus bicalutamide (BC). NCOA2-
silencing cells showed an increased proliferation compared with non-
silencing control cells and those with silencing androgen receptor (AR).
LNCaP cells with silencing AR showed decreased proliferation
compared with those silencing NCOA2. *P < 0.01 (Kruskal-Wallis test)
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for siRNA NCOA2 #1 (siNCOA2 #1), #2 (siNCOA2 #2), and #3 (siNCOA2 #3),
respectively. Based on this result, siRNA NCOA2 #2 was selected, and the
relevant data were indicated in Fig. 5. (DOC 54 kb)
Additional file 2: Table S1. Ct values of gene expression assessed by
quantitative PCR in VCaP cells cultured with dihydrotestosterone-added
media. Delta-delta Ct value was calculated from the following formula:
delta(target gene Ct – internal control Ct) with specific cell culture media
- delta(target gene Ct – internal control Ct) with standard cell culture
media. (DOC 32 kb)
Additional file 3: Table S2. Ct values of quantitative PCR in VCaP cells
cultured with dihydrotestosterone- and bicalutamide-added media. (DOC
31 kb)
Additional file 4: Table S3. Ct values of quantitative PCR in VCaP cells
cultured with dihydrotestosterone- and hydroxyflutamide-added media.
(DOC 31 kb)
Additional file 5: Table S4. Ct values of quantitative PCR in LNCaP cells
cultured with dihydrotestosterone-added media. (DOC 31 kb)
Additional file 6: Table S5. Ct values of quantitative PCR in LNCaP cells
cultured with dihydrotestosterone- and bicalutamide-added media. (DOC
31 kb)
Additional file 7: Table S6. Ct values of quantitative PCR in LNCaP cells
cultured with dihydrotestosterone- and hydroxyflutamide-added media.
(DOC 31 kb)
Additional file 8: Figure S2. Full membranes of Western blotting
(corresponding to Fig. 7). The membrane in the left panel showed
NCOA2 staining part, and the right showed actin beta staining part.
Starting from the left lane, NCOA2 expressions in LNCaP with
bicalutamide and without bicalutamide, and positive control were
shown. Twenty-seven ug of Jurkat cell lysate (Catalog #611451, BD Biosci-
ences, Franklin Lakes, NJ, USA) was used as positive control. Densitometry
data of Western blotting were attached below them. (DOC 1266 kb)
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